Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

Science Direct ^ | 09/2021 | A.D.Santin, D.E.Scheim, P.A.McCullough, M.Yagisawa, T.J.Borody5

[SeekAndFind]

Abstract

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Introduction

The 2015 Nobel prize for the discovery of ivermectin (IVM) and an antimalarial treatment was the Nobel committee’s first award for treatment agents for infectious diseases since the one in 1952 for streptomycin [1]. A macrocyclic lactone of multifaceted potency [2,3], IVM as deployed worldwide since 1987 has made major inroads against two devastating tropical diseases, onchocerciasis and lymphatic filariasis [4]. During the year since IVM treatment was first applied to COVID-19, another global scourge [5], results from more than 20 randomized clinical trials (RCTs) of IVM treatment of COVID-19 have been reported [2,6,7], with inpatient and outpatient treatments of COVID-19 conducted in 25 countries [2]. A likely biological mechanism has been indicated to be competitive binding with SARS-CoV-2 spike protein sites, as reviewed [8,9].

Recently, Dr Satoshi Omura, the Nobel co-laureate for the discovery of IVM, and colleagues conducted a comprehensive review of IVM clinical activity against COVID-19, concluding that the preponderance of the evidence demonstrated major reductions in mortality and morbidity [2]. Our review of that evidence, updated with consideration of several new studies, supports the same conclusion.

Animal studies for IVM treatment of SARS-CoV-2 and a closely related betacoronavirus

A framework for the examination of clinical IVM treatment results for COVID-19 is provided by related animal studies using IVM at low human-equivalent doses. In golden hamsters that were intranasally inoculated with SARS-CoV-2, causing symptomatic COVID-19 infections, concurrent dosing with IVM significantly reduced the severity of clinical signs (p < 0.001). While viral load was not reduced, these improvements included one-third of the incidence of anosmia and sharp reductions in the Il-6/Il-10 ratio in lung tissue [10]. In another animal model, mice were infected with mouse hepatitis virus MHV-A59 [11], a betacoronavirus strain that does not express hemagglutinin esterase [12], like SARS-CoV-2, SARS-CoV, and MERS [8]. Whereas infected mice had severe histopathological liver damage, IVM-treated mice had half the hepatic viral load and minimal liver damage, not significantly different than that observed in uninfected controls.

RCTs for IVM treatment and prevention of COVID-19

More than 20 RCTs for IVM treatment of COVID-19 have been conducted to date, as cited above. A search of Google Scholar for meta-analyses of IVM treatment studies of COVID-19 that appeared in 2021 [13] yielded seven such studies that drew conclusions from RCTs only [6,[14], [15], [16], [17], [18], [19]]. The relative risk (RR) of mortality with IVM treatment vs. controls as calculated in four of these meta-analyses using Cochrane analysis methodology ranged from 0.25 to 0.37, with a mean of 0.31 [6,14,15,19]. The three other meta-analyses reported odds ratios of 0.16, 0.21 and 0.33, with a mean of 0.23 [[16], [17], [18]]. Six of these seven meta-analyses concluded that there was a significant [6,[14], [15], [16]] or possible [17,18] indication of the efficacy of IVM in reducing COVID-19 mortality. One found no evidence of IVM efficacy in its first version [20], reporting an RR of 1.11 for IVM treatment vs. controls, and stuck with that finding even after changing this RR value to 0.37 and correcting switched treatment and control deaths it had misreported for one study [21] in a revised version [19]. Among the most recent and comprehensive of these seven meta-analyses reported a pooled total of 31 deaths among 1101 subjects in IVM treatment groups and 91 deaths among 1064 controls from 11 RCTs, amounting to a 67% reduction in mortality, with a statistical significance for an overall effect of p = 0.005 [16]. The RCT that used the largest dose of IVM, 400 μg/kg on each of days 1-4 [22], had 2 vs. 24 deaths in the treatment vs. control groups (n = 200 each).

An objection that had been raised earlier in 2021 to the preponderance of clinical evidence for the efficacy of IVM treatment of COVID-19 as summarized above was that none of these RCTs had been published in mainstream peer-reviewed scientific journals [23]. Closing that gap, however, was the publication in 2021 in journals from major scientific publishers of five such RCTs for COVID-19 treatment [[24], [25], [26], [27], [28]], each showing multiple clinical benefits for IVM vs. controls, most of these to statistical significance at p < 0.002. Also published in 2021 were three other RCTs for IVM treatment of COVID-19: one that reported briefer hospital stays for IVM treatment short of statistical significance (p = 0.08) [29], another that compared IVM with two other drug treatment groups but not a placebo group and found no benefit [30], and an additional study conducted in Cali, Columbia with mix-ups between treatment and placebo doses as described below.

Another objection that has been raised to the RCT evidence supporting IVM efficacy was that study populations were too small [31]. Yet, it is well known in clinical trial design that highly effective drugs will establish statistically significant results with smaller sample sizes, with larger study populations required for minimally effective drugs [32,33]. But for a drug with a more modest RR of 75%, for example, the treatment and control arms would need more than 3800 subjects each to yield the same statistical significance [33]. Although large study populations are useful to screen for adverse effects (AEs) of new drugs, IVM has been used safely in 3.7 billion doses worldwide since 1987 [2,3] and is well tolerated even at much greater doses than the standard single dose of 200 μg/kg [34,35]. It has been used in RCTs for COVID-19 treatment at cumulative doses of 1500 μg/kg [36], 1600 μg/kg [22] and 3000 μg/kg [37] over 4 or 5 days with only small percentages of mild or transient adverse effects.

Among these RCTs that established safety for high-dose IVM treatment of COVID-19 was one conducted in Cali, Columbia, with generally mild COVID-19 cases, median age 37, having only one death in the control group [36]. The study found no statistically significant symptom improvements with IVM treatment yet reported a striking anomaly: AEs distinctive for its high IVM dose, described in the study protocol as ‘security parameters’ for its IVM use, occurred at almost identical rates in its IVM and placebo arms. These included transient incidences of blurred vision (11.3%, 11.6%) and dizziness (35.6%, 34.3%). These indications of IVM use in controls occurred as over-the-counter sales of IVM surged in the study region during the study period (Supplementary Table 1). Further questions as to the study’s treatment/control boundaries were raised by the mistaken substitution of IVM for placebo for 38 patients, discovered by the lead pharmacist a month after the fact (study, p. 3; study protocol supplement, p. 43). In addition, blinding was breached by the use of the dextrose-saline solution as the placebo for 64 control patients (IVM tastes distinctively bitter), while the composition of the replacement placebo solution was not specified [38].

Supporting the findings of IVM efficacy in COVID-19 treatment as summarized above were indications of activity against SARS-CoV-2 in prevention studies. Three RCTs evaluated the prophylactic effect of IVM administered to cohorts of 100 [22], 117 [39] and 203 [40] subjects exposed to COVID-19 patients. These studies, all using IVM in doses of at least 150 μg/kg per week, reported statistically significant reductions in COVID-19 incidences, with respective RRs of 20%, 26% and 13% as compared with controls, and greater reductions in incidences of moderate and severe cases. Another RCT for COVID-19 prevention administered just one dose of IVM at 12 mg (about 150 μg/kg) to 617 subjects on day one of a 42-day observation period, while three other preventative regimens were each administered daily over that period [41]. IVM at that single low dose yielded the best results of these four regimens, with highly statistically significant reductions of close to 50% in both symptomatic COVID-19 and acute respiratory symptoms vs. controls.

14-fold reductions in excess deaths with IVM use in Peru, then 13-fold increase after IVM restricted

The clinical experience of IVM treatments of COVID-19 in 25 countries extends far beyond the RCT results summarized, yet incomplete tracking and lack of control data exclude most of this for evaluation. The record of nationally authorized such treatments in Peru provides a notable exception [42]. In ten states of Peru, mass IVM treatments of COVID-19 were conducted through a broadside, army-led effort, Mega-Operación Tayta (MOT), that began on different dates in each state. In these MOT states, excess deaths dropped sharply over 30 days from peak deaths by a mean of 74%, in close time conjunction with MOT start date (Fig. 1B). In 14 states of Peru having locally administered IVM distributions, the mean reduction in excess deaths over 30 days from peak deaths was 53%, while in Lima, which had minimal IVM distributions during the first wave of the pandemic due to restrictive government policies there, the corresponding 30-day decrease in excess deaths was 25%.

Fig. 1. A) Excess all-cause deaths (all ages), the national population of Peru. These decreased 14-fold from 1st August through 1st December 2020; then, after IVM use was restricted, increased 13-fold through 1st February. For A and B, y values are 7-day moving averages; for B and C, ages ≥60. Data are from Peru’s National Death Information System (SINADEF). (B) Drops in excess deaths for all states of operation MOT, an army-led program of mass IVM distributions, but Pasco, which had them on three dates. • MOT start date; ▴ peak deaths; ▪ day of peak deaths +30 days. Junin distributed IVM through local channels 13 days before MOT start. (C) Reductions in excess deaths at +30 days after peak deaths for the 25 states by extent of IVM distributions: maximal-MOT (Image 1), mean -74%; moderate-local distributions (Image 2), mean -53%; and minimal-Lima (Image 3), -25%. The absolute value of these reductions by state correlated with extent of IVM distributions with Kendall τb = 0.524, p < 0.002 (Spearman rho = 0.619, p < 0.001). All these data are from publicly accessible Peruvian national databases, with associated frozen datasets available from the Dryad data repository [42].

---

Reductions in excess deaths by state (absolute values) correlated with the extent of IVM distribution (maximal-MOT states, moderate-local distributions, and minimal-Lima) with Kendall τb = 0.524, p < 0.002, as shown in Fig. 1C. Nationwide, excess deaths decreased 14-fold over four months through 1st December 2020. After a restrictive IVM treatment policy was enacted under a new Peruvian president who took office on 17th November, however, deaths increased 13-fold over the two months following 1st December through 1st February 2021 (Fig. 1A). Potential confounding factors, including lockdowns and herd immunity, were ruled out using Google community mobility data, seropositivity rates, population densities and geographic distributions of SARS-CoV-2 genetic variations and by restricting all analysis except that for Fig. 1A to ages ≥ 60. Excess deaths were used in all analyses rather than COVID-19 case fatalities as gross underreporting of pandemic deaths by case fatalities was known to the Peruvian Ministry of Health since July 2020 [43]. This disparity has been consistently manifested in the national health database figures for COVID-19 case fatalities vs. all natural-cause deaths since that date [42].

IVM-based combination treatments and other research in progress

Combination treatments using IVM and adjuncts have shown indications of efficacy against COVID-19 in RCTs conducted to date [24,44]. Results using IVM, doxycycline and zinc to treat serious and critical cases having spO2 ≤ 90 prior to treatment, with spO2 changes tracked 24 hours after treatment, will be reported by TJB with Sabine Hazan, MD. Pronounced improvements of serious COVID-19 symptoms within 1–2 days after IVM administration have been observed in several patients treated by the lead author (ADS), and studies to objectively track such short-term clinical benefits of IVM for COVID-19 are underway. Information on other combination treatments using IVM with agents such as fluvoxamine, for which clinical studies also indicate significant benefits [45], is provided by the USA-based FLCCC alliance (https://covid19criticalcare.com).

The curative potential of combination therapy was demonstrated in a medical breakthrough of three decades prior for another disease, peptic ulcers, for which the discovery of its underlying bacterial cause, Helicobacter pylori, was honoured with the Nobel Prize for Medicine in 2005. In 1990, Dr Thomas J. Borody published the original clinical trial of a combination treatment for H. pylori, achieving a 96% cure rate for a triple therapy consisting of three repurposed drugs, bismuth subcitrate and two antibiotics [46]. Between 1990 and 2015, an estimated 18,665 deaths were prevented by the timely application of this triple therapy for peptic ulcer disease in Australia [47]. After the expiration of the patents for two palliative drugs for this condition, Tagamet and Zantac [48], which had each earned billions of dollars, triple therapy became the standard of care for peptic ulcers in the rest of the world by the late 1990s.

Conclusion

We believe that the evidence to date supports the worldwide extension of IVM treatments for COVID-19, complementary to immunizations. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, as reviewed [8], possibly yielding full efficacy against emerging viral mutant strains. IVM has been safely used in 3.7 billion doses since 1987, well tolerated even at much greater than standard doses [34,35] and used without serious AEs in the three high-dose COVID-19 treatment studies noted above [34,36,37]. In the current international emergency of COVID-19, with mutant viral strains, vaccination refusals and potentially waning immunities over months presenting new challenges, IVM can be an effective component of the mix of therapeutics deployed against this pandemic.

Funding

No funding was received for this perspective.

Ethical approval and consent to participate

This is a review and ethical approval was not required.

Transparency declaration

TJB is a principal in Topelia Therapeutics (Ventura, California), which seeks to commercialize cost-effective treatments for COVID-19, including IVM. All other authors report no conflicts of interest.

---

CLICK ABOVE ARTICLE LINK FOR THE REFERENCES

[SeekAndFind]

Appendix A. Supplementary data: The following is/are the supplementary data to this article:

Download : Download Acrobat PDF file (326KB)

[FormerFRLurker]

Thanks for this. Ivermectin is an FDA-approved drug for humans, so there’s no reason not to try it. As former President Trump said, albeit in a different context, “What have you got to lose?”. Ultimately I trust the guys and gals with medical degrees far more than I trust the politicians.

[SeekAndFind]

About the Authors:

1) A.D.Santin

Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, USA

2) D.E. Scheim

US Public Health Service, Inactive Reserve, Blacksburg, VA, USA

3) P.A. McCulloagh

Texas A & M College of Medicine, Dallas, TX, USA

4) M. Yagisawa

Ōmura Satoshi Memorial Institute, Infection Control Research Center, Kitasato University, Tokyo, Japan

5) T.J. Borody

Centre for Digestive Diseases, New South Wales, Australia

[SeekAndFind]

About the Authors:

1) A.D.Santin

Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, USA

2) D.E. Scheim

US Public Health Service, Inactive Reserve, Blacksburg, VA, USA

3) P.A. McCulloagh

Texas A & M College of Medicine, Dallas, TX, USA

4) M. Yagisawa

Ōmura Satoshi Memorial Institute, Infection Control Research Center, Kitasato University, Tokyo, Japan

5) T.J. Borody

Centre for Digestive Diseases, New South Wales, Australia

[Jane Long]

Thanks for posting.

[SeekAndFind]

Ping for your interest

[Eagles6]

Bttt

[TheDon]

Anyone fortunate enough to have their physician prescribe Ivermectin for them?

[Karl Spooner]

Now here is something that God sent, Governor Hochul.

Ivermectin:
The avermectin family of compounds was discovered by Satoshi Ōmura of Kitasato University and William Campbell of Merck. In 1970, Ōmura isolated unusual Streptomyces bacteria from the soil near a golf course along the south east coast of Honshu, Japan.[7]

Ōmura sent the bacteria to William Campbell, who showed that the bacterial culture could cure mice infected with the roundworm Heligmosomoides polygyrus.

[7] Campbell isolated the active compounds from the bacterial culture, naming them "avermectins" and the bacterium Streptomyces avermitilis for the compounds' ability to clear mice of worms (in Latin: a 'without', vermis 'worms').[7]

Of the various avermectins, Campbell's group found the compound "avermectin B1" to be the most potent when taken orally.[7]

https://en.wikipedia.org/wiki/Ivermectin#Chemistry

[RushIsMyTeddyBear]

No.

[Bobalu]

Humble beginnings, from something found in dirt to a multi-use drug with many important applications..

Penicillin had a similar birth.. from mold growing on cantaloupe rinds in a laboratory sink to indispensable antibiotic miracle drug. Although it would be a sub-optimal choice for treating pneumonia today it was once basically the only treatment... the choice now would be something like Doxycycline.

[Basket_of_Deplorables]

It’s the cure for most people, for early covid. And it works prophylactically. I’m on it, the horse paste lol.

[Prince Caspian]

I found a doctor that was willing to prescribe Ivermectin, but so far I haven’t found a pharmacist that will fill it. Many pharmacists are willing and even sympathetic. However, they are being overridden or directed at a higher level to not prescribe. They cite safety, which can clearly be shown to be untrue. When pointed out that the drug has been around for 35 years with no safety issues, they then shift to claim there has been no trials showing Ivermectin to be effective for covid. That’s not true either. There are trails that show effectiveness. They just don’t want to look at them.

Welcome to the Brave New World where medical personnel surrender their professional integrity to become cringing cowards in the face of the political agenda of an insidiously corrupt, self-appointed elite. Utopia is surely just around the corner.

[Bobalu]

[Chad C. Mulligan]

Anyone fortunate enough to have their physician prescribe Ivermectin for them?

Yes, my older daughter's physician did. She's a PureBlood, like me. My own Primary Care Physician declined, but pointed me to a nearby hospital that is offering the monoclonal antibody treatment.

Neither of us have managed to catch the bloody virus, however

[JudgemAll]

Lmao. I went to tractor supply and they are plastering the shelves with warnings against human use and that it does not treat covid.

[MayflowerMadam]

My niece in Georgia has doctors who have prescribed it. With the certain knowledge that our communist overlords in the medical industrial complex are lying to us at every turn, they use concierge providers.

I’m not sure, but I think that even with prescriptions, having pharmacists turn it over is becoming a problem.

[Candor7]

The key to Ivermectin working is to have Ivermectin at a level of greater than 160 nanograms / liter in the blood. (One billionth (10−9) of a gram.)

Ivermectin taken with food,has been discovered to be very effective at killing the virus at this level of dosage , which in this study is 6 mg per kilo of body weight :

“High Dose Ivermectin And COVID-19: High Doses, Systemic Concentrations, And SARS-CoV-2 Viral Loads!”

https://www.youtube.com/watch?v=wsJPZPB93Qc

************************************

Be prepared:

The vaccine is a dead end path to coping with Covid.

Eventually it will not work at all.

Immunity is 27 times more effective than any Vax.

So how do we get immunity? We use drug therapy once infected, and we all sooner or later will be infected, its like the common cold, unavoidable.

The best so far is Ivermectin based drug therapy.

The proper approach to conquering the virus is one like we use for malaria.

Ivermectin therapy should be over the counter, non prescription, and used according to established protocols with which we can educate the public.

If you cannot get a physician’s prescription, you can order it here:( Use Pay Pal)

1) Zivirdo Kit:

https://dir.indiamart.com/search.mp?ss=Zivirdo&prdsrc=1&countryiso=USA ( get enough to make sure your dosage is right for your weight...carefully read the protocol linked below )

2) Ivermectin Tabs ( get 12 mg tabs)

https://dir.indiamart.com/search.mp?ss=ivermection+12+mg&prdsrc=1&src=as-popular%3Akwd%3Divermect12%3Apos%3D1%3Acat%3D-2%3Amcat%3D-2&qu-cx=1&countryiso=USA

***************************

Protocols to follow for both Prophylaxis and Therapy for Infection:( read it in detail before ordering)

https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-I-MASK-Protocol-v4-2020-11-22.pdf

Ivermectin is no longer a banned treatment by the CDC. They are just “not recommending” it.The reason that the government is so afraid of Ivermectin is that it likely clears the circulation system of ALL stick proteins whether generated by the VAX or by the Virus. So it will likely reverse the effect of the jab.

You will need over the counter Zinc, Vitamin D and Quercetin supplements.Available on line or at larger drug stores.

Hundreds of Feepers stocked up over the last 6 months.

********************************

https://www.researchgate.net/publication/343390023_Ivermectin_docks_to_the_SARS-CoV-2_spike_receptor-binding_domain_attached_to_A

There is reasonably solid evidence that ivermectin docks to the spike protein itself to prevent binding to the ACE2 receptor which is the primary pathology causing the tissue damage and clots related to SARS-CoV-2. Therefore, this is also an implication that this ability of ivermectin to disable the binding of the Spike protein including the vaccine-produced spike proteins. This binding of ivermectin to disable the spike protein is also preserved even with the newer spike protein mutations, but its activity against the original Wuhan spike protein,(the one vaccines were designed to produce) is fairly well studied at this point.

Abstract:

Background/Aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. Materials and Methods: We used the program AutoDock Vina Extended to perform the docking study. Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08. Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.

The following video [ https://www.youtube.com/watch?v=11Bl2v3BR2M ] explains the multiple mechanisms of the activity of Ivermectin including the ability of the body to maintain its basic defense of the cell nucleus in preserving the body’s ability to produce antiviral proteins, inhibition of RNA dependant RNA polymerase which inhibits the replication of viral RNA (possibly including that from the mRNA vaccine package), the stat 3 human signaling pathway which inhibits the production of blood clots also possibly mitigating some of the vaccines most dangerous side effects. Also discussed is the inhibition of the CD147 pathway by Ivermectin which again may block the clumping of platelets due to spike protein either from the virus or possibly the vaccines.

Note: Ivermectin therapy likely will gradually rid the body of spike proteins altogether, something to remember for those who might have residual side effects from mRNA vaccine.

******************************************************
Effective dosage of Ivermectin is 0.6 mg per kilo of body weight instead of the 0.2 recommended in the IMASK protocol.

Protocols to follow for both Prophylaxis and Therapy for Infection:( read it in detail )

https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-I-MASK-Protocol-v4-2020-11-22.pdf

The study is here:
“High Dose Ivermectin And COVID-19: High Doses, Systemic Concentrations, And SARS-CoV-2 Viral Loads!”

https://www.youtube.com/watch?v=wsJPZPB93Qc

*************************

( 0.6 mg per kilo of body weight yields greater than 160 nanograms of Ivermectin per liter of blood, at that level it eliminated the virus...side effects. rarely a rash, or rare salt deficiency ( NaCl).

**************************************************

[Candor7]

See my post # 19 below, Sources of Ivermectin.Order takes about 30 days to arrive.